Combination of intravenous immunoglobulins and lenalidomide in the treatment of scleromyxedema

Multiple skin‐colored papules on the face and upper extremities

“…It may include melphalan, corticosteroids, plasmapheresis, acitretin, intravenous immunoglobulins, thalidomide, methotrexate, cyclophosphamide, cyclosporine, phototherapy and laser therapy. Topical tacrolimus ointment and topical corticosteroids have also been used successfully as a treatment option [9][10][11][12][13][14][15]. Systemic therapy with neotigason was discussed with our patient, but she decided against it and the proposed follow-up.…”

Scleromyxedema: long‐term follow‐up after high‐dose melphalan with autologous stem cell transplantation

“…However, the response to IVIG is often temporary and requires long‐term maintenance therapy to prevent relapses . Lenalidomide combined with IVIG has achieved complete remissions in scleromyxedema that have persisted for at least 2 years . Allogeneic stem cell transplantation also resulted in a complete response in a patient with scleromyxedema and severe neurological features .…”

Lenalidomide treatment of cutaneous lupus erythematosus: the Mayo Clinic experience

“…Its mechanism of action is similar to that of thalidomide and includes altering cytokine production (inhibition of tumor necrosis factor‐ α ), regulating T cell stimulation, and augmenting natural killer cell cytotoxicity . It has also been reported to be of use in the treatment of severe CLE, as well as refractory prurigo nodularis, scleromyxedema, lupus pernio, and generalized granulomatous dermatitis …”

“…17 It has also been reported to be of use in the treatment of severe CLE, [18][19][20][21] as well as refractory prurigo nodularis, scleromyxedema, lupus pernio, and generalized granulomatous dermatitis. [22][23][24][25][26] Prior case series describe lenalidomide as an effective treatment of refractory CLE. The purpose of this study was to review the present authors' institutional experience with lenalidomide in the treatment of patients with CLE that was unresponsive to prior therapies or in patients who were intolerant of prior therapies.…”